Core Viewpoint - Eddie Pharmaceuticals reported a significant revenue increase of 72.49% in 2025, driven by rising income from innovative anti-HIV drugs and operational data from its subsidiary, Nanda Pharmaceuticals. The company's losses narrowed from 141 million yuan in 2024 to 19.73 million yuan in 2025, marking an 86.02% reduction in loss margin [1][2]. Group 1: Financial Performance - The company achieved a revenue of 721 million yuan in 2025, with a year-on-year growth of 72.49% [2]. - The loss for 2025 was reduced to 19.73 million yuan from 141 million yuan in 2024, indicating a significant improvement in financial health [2]. - Eddie Pharmaceuticals turned a profit in operating income for the first time, reporting 47.74 million yuan in 2025 [2]. Group 2: Anti-HIV Drug Segment - Revenue from innovative anti-HIV drugs is projected to reach 285 million yuan in 2025, representing a 90.34% increase year-on-year [3]. - The anti-HIV drugs are expected to account for 39.53% of the company's total revenue in 2025 [3]. - The sales of anti-HIV new drugs nearly doubled from 150 million yuan in 2024 to 285 million yuan in 2025 [3]. Group 3: Nanda Pharmaceuticals Contribution - Nanda Pharmaceuticals, a subsidiary, is expected to generate 300 million yuan in revenue for 2025, reflecting a 227.38% increase year-on-year [4]. - Eddie Pharmaceuticals has made several acquisitions to increase its stake in Nanda Pharmaceuticals, enhancing its control and management efficiency [4][6]. - The strategic focus on Nanda Pharmaceuticals aims to solidify Eddie Pharmaceuticals' position in the human protein sector, particularly in the production of urokinase and other biopharmaceuticals [5][6].

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), has announced a strong performance forecast for the fiscal year 2025, highlighting significant revenue growth and a substantial reduction in losses, driven by its dual strategy of "HIV new drugs + human-derived proteins" [1][3] Financial Performance - The company expects a total revenue of approximately 721.01 million yuan for 2025, representing an increase of about 303.21 million yuan, or 72.57% year-on-year [1] - The core product, the innovative anti-HIV drug business, is projected to generate revenue of 285.31 million yuan, reflecting a year-on-year surge of 90.34% [1] - The subsidiary, Nanda Pharmaceutical, is anticipated to contribute approximately 299.84 million yuan in revenue, with a year-on-year increase of 227.38% [2] Loss Reduction and Profitability - The expected net loss attributable to the parent company is estimated to be between 16 million and 24 million yuan, a reduction of approximately 125.20 million to 117.20 million yuan compared to the previous year, marking a decline in loss margin of 88.67% to 83.00% [2] - The adjusted net loss, excluding non-recurring items, is projected to be between 17.20 million and 25.20 million yuan, also showing a significant reduction from the previous year [2] Strategic Initiatives - The impressive performance is attributed to the company's focus on core sectors and the effective implementation of its dual strategy, which has led to a notable increase in gross profit from core operations by approximately 267 million yuan [3] - The company is enhancing its academic promotion efforts and optimizing its commercialization channels to accelerate the market penetration of its core products [3] - Aidi Pharmaceutical is advancing its innovative drug pipeline, with ongoing clinical trials for new HIV integrase inhibitors and long-acting pre-exposure prophylaxis drugs, which are expected to drive long-term growth [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [6]. Core Insights - The company plans to raise up to 185 million yuan through a simplified procedure for issuing A-shares, with funds allocated for acquiring a 22.2324% stake in Nanda Pharmaceutical and for supplementing working capital [6]. - The acquisition of Nanda Pharmaceutical is expected to enhance the company's integrated strategy of "raw materials + formulations," increasing its direct stake to 73.358% [6]. - The company has a robust pipeline of human-derived protein products, including new drugs AD010, AD108, and ADB116, with AD108 and ADB116 receiving clinical approval in 2025 [6]. - The company showcased its third-generation integrase product ACC017 at the J.P. Morgan conference, highlighting its competitive edge in the HIV treatment market [6]. Financial Data and Profit Forecast - Total revenue is projected to grow from 418 million yuan in 2024 to 1.263 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 26.7% [5]. - The net profit is expected to turn positive in 2025, reaching 7 million yuan, and further increasing to 166 million yuan by 2027, reflecting a significant growth trajectory [5]. - The gross margin is forecasted to improve from 54.9% in 2024 to 75.2% in 2027, indicating enhanced operational efficiency [5]. - The return on equity (ROE) is anticipated to rise from -14.4% in 2024 to 13.4% in 2027, suggesting a recovery in profitability [5].